Update in large cell lymphoma: understanding the pathology report

Hsi, Eric D.

doi:10.1182/asheducation-2015.1.605

Cited by 4 publications

(5 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Internal necrosis was more commonly found in ENKTL (85%) than that in DLBCL (15%). Pathological reasons include that the ENKTL has the angiocentric and angiodestructive growth pattern that can easily cause the coagulative necrosis and ulcer, whereas the DLBCL has been characterized by sheets of large cleaved and/or noncleaved cells [19]. Septal enhancement pattern was found in 41% of DLBCLs, while none of ENKTLs.…”

Section: Discussionmentioning

confidence: 99%

Differential diagnosis of sinonasal extranodal NK/T cell lymphoma and diffuse large B cell lymphoma on MRI

Chen

Wang

et al. 2020

Neuroradiology

View full text Add to dashboard Cite

Purpose To evaluate whether imaging features on conventional magnetic resonance imaging (MRI) can differentiate sinonasal extranodal natural killer/T cell lymphomas (ENKTL) from diffuse large B cell lymphoma (DLBCL). Methods Consecutively, pathology-proven 59 patients with ENKTL and 27 patients with DLBCL in the sinonasal region were included in this study. Imaging features included tumor side, location, margin, pre-contrast T1 and T2 signal intensity and homogeneity, post-contrast enhancement degree and homogeneity, septal enhancement pattern, internal necrosis, mass effect, and adjacent involvements. These imaging features for each ENKTL or DLBCL on total 86 MRI scans were indicated independently by two experienced head and neck radiologists. The MRI-based performance in differential diagnosis of the two types of lymphomas was evaluated by multivariate logistic regression analysis. Results All ENKTLs were located in the nasal cavity, with ill-defined margin, heterogeneous signal intensity, internal necrosis, marked enhancement of solid component on MRI, whereas DLBCLs were more often located in the paranasal sinuses, with MR homogenous intensity, mild enhancement, septal enhancement pattern, and intracranial or orbital involvements (all P < 0.05). Using a combination of location, internal necrosis and septal enhancement pattern of the tumor in multivariate logistic regression analysis, sensitivity, specificity, and accuracy in differential diagnosis of ENKTL and DLBCL were 100%, 79.4%, and 91.9%, respectively, for radiologist 1, and were 98.3%, 81.5%, and 93.0%, respectively, for radiologist 2. Conclusion MRI can effectively differentiate ENKTL from DLBCL in the sinonasal region with a high diagnostic accuracy.

show abstract

Section: Discussionmentioning

confidence: 99%

Differential diagnosis of sinonasal extranodal NK/T cell lymphoma and diffuse large B cell lymphoma on MRI

Chen

Wang

et al. 2020

Neuroradiology

View full text Add to dashboard Cite

show abstract

“…11,[13][14][15][16] Secara molekular, klasifikasi DLBCL dilakukan melalui gene expression profiling (GEP) dan pemeriksaan imunohistokimia menjadi subtipe Germinal Center B-cell (GCB) dan Activated B-cell (ABC/non-GCB). 2,9,[17][18][19] Alat prognostik utama yang digunakan pada pasien DLBCL yaitu International Prognostic Index (IPI), meliputi faktor usia, stadium tumor (Ann Arbor staging), kadar serum lactate dehydrogenase (LDH), status performa pasien berdasarkan Eastern Cooporative Oncology Group (ECOG), dan jumlah area ekstranodal yang terkena. 16,[20][21][22][23] CD30, disebut juga tumour necrosis factor receptor super family 8 (TNFRSF8), pertama kali diidentifikasi pada sel Hodgkin Reed-Stenberg limfoma Hodgkin klasik, selanjutnya pada limfoma sel besar anaplastik.…”

Section: Latar Belakangunclassified

“…CD30 memberikan hasil positif jika diekspresikan oleh sel tumor lebih dari 0%. Penampakan hasil negatif dan positif CD30 pada DLBCL dapat dilihat pada Gambar 1.PEMBAHASANDLBCL merupakan penyakit heterogen dengan berbagai morfologi, imunofenotipe, klinis dan biologi, yang dapat memberikan respons terapi bervariasi 18,19,[33][34][35]. Pada penelitian ini, CD30 diekspresikan oleh 13 kasus (37.1%) menggunakan cut off di atas 0%.…”

unclassified

Ekspresi CD30 pada pasien Diffuse Large B-cell Lymphoma di RSUP Dr. Kariadi Semarang

Winoto¹

2020

juke

View full text Add to dashboard Cite

EKSPRESI CD30 PADA PASIEN DIFFUSE LARGE B-CELL LYMPHOMA DI RSUP DR. KARIADI SEMARANG Jessica Winoto1; Udadi Sadhana2; Dik Puspasari2; Siti Amarwati2; Devia Eka Listiana2; Hermawan Istiadi2 Residen Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia1; Staf pengajar Departemen Patologi Anatomi, Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia2 Corresponding email: jessicawin11@gmail.com AbstrakLatar Belakang: Diffuse Large B-Cell Lymphoma (DLBCL) merupakan penyakit heterogen dengan berbagai morfologi, sifat biologi dan klinis, yang memiliki respon terapi bervariasi. Beberapa penelitian melaporkan adanya ekspresi CD30 pada DLBCL berhubungan dengan ketahanan hidup yang lebih baik. Namun hal ini masih perlu dilakukan penelitian lebih lanjut. Tujuan penelitian ini untuk mengevaluasi ekspresi CD30 pada pasien DLBCL di RSUP Dr. Kariadi.Metode penelitian: Penelitian ini mengevaluasi ekspresi CD30 pada 35 pasien DLBCL di RSUP Dr. Kariadi periode Januari 2017 hingga Desember 2017 menggunakan cut off >0%. Data klinik yang diambil yaitu usia saat terdiagnosis, lokasi tumor, stadium penyakit, subtipe sel asal, dan ketahanan hidup 2 tahun. Analisis data menggunakan uji chi square.Hasil: Dari 35 kasus, CD30 diekspresikan oleh 13 kasus (37.1%). Ekspresi CD30 lebih tinggi pada pasien dengan usia ?60 tahun (P=0.03), lokasi ekstranodal (P=0.78), stadium awal (P=0.89), dan subtipe non-GCB (P=0.97). Kelompok CD30 positif memiliki ketahanan hidup yang lebih baik dibandingkan CD30 negatif (P=0.90).Kesimpulan: Ekspresi CD30 memiliki hubungan yang bermakna dengan usia ?60 tahun. Pasien DLBCL dengan CD30 positif memiliki ketahanan hidup yang lebih baik dibandingkan CD30 negatif, namun tidak bermakna. Kata Kunci : DLBCL, CD30, ketahanan hidup CD30 EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN KARIADI GENERAL HOSPITAL SEMARANG Jessica Winoto1; Udadi Sadhana2; Dik Puspasari2; Siti Amarwati2; Devia Eka Listiana2; Hermawan Istiadi2 Resident of Anatomical Pathology Department, Faculty of Medicine Diponegoro University, Semarang Indonesia1; Lecturer of Anatomical Pathology Department, Faculty of Medicine Diponegoro University, Semarang Indonesia2 Corresponding email: jessicawin11@gmail.com AbstractBackground: Diffuse Large B-Cell Lymphoma (DLBCL) is a heterogenous disease containing morphology, biologically dan clinically distinctive subgroups that show variable response to therapy. Many studies showed that CD30 expression in DLBCL is associated with superior overall survival. However, prognostic value of CD30 expression in DLBCL still needs further studies. The aim of this study was to determine the expression of CD30 in DLBCL patients in Kariadi General Hospital.Methods: This study identified CD30 expression in 35 cases of DLBCL diagnosed between January 2017 and December 2017, using cut off values >0%. Clinical data collected including age of diagnosis, tumour location, stage of disease, cell of origin subtype, and two-year overall survival. Data were analyzed using chi square test. Results: CD30 expression was found in 13 (37.1%) cases. CD30 positivity was higher in age ?60 years (P=0.03), extranodal location (0.78), early stage (P=0.89), and non-GCB subtype (P=0.97). CD30-positve DLBCL had a better survival than CD30-negative DLBCL (P=0.90).Conclusion: CD30 positivity was significantly associated with age ?60 years. CD30-positve DLBCL had a better survival than CD30-negative DLBCL, but not significant. Keywords: DLBCL, CD30, overall survival

show abstract

“…In particular, co‐expression of BCL2 (≥50% of tumor cells) and MYC (≥40% of tumor cells) is associated with a poor prognosis, independent of other clinical risk factors in patients treated with standard immuno‐chemotherapy. Due to this aggressive behavior, clinical trials are also being developed for these so‐called “double‐expressor” (DE) cases …”

Section: B‐cell Lymphomas/leukemiasmentioning

confidence: 99%

2016 WHO Classification update—What's new in lymphoid neoplasms

Hsi

2017

Int J Lab Hematology

View full text Add to dashboard Cite

In the 8 years since the publication of the 4th edition of the WHO Classification of Hematopoietic and Lymphoid Tumours in 2008, there has been rapid accumulation of knowledge in the molecular genetics, biology, clinical behavior of many hematologic malignancies. Concepts and models have advanced to the point at which updates were deemed necessary prior to the formal WHO process of publication of a 5th edition as part of the WHO "blue book" series. This overview will focus on lymphoid tumors and highlight important changes and updates to these neoplasms. (Table 1) to these neoplasms as recently published. and miRNA signatures were similar. The 3-year progression free survival was 95% for MBL patients vs 80% for Rai stage 0 patients (hazard ratio 4.5, 95% confidence interval 2.1-9.5, P < .0001). This study showed that there is a great similarity biologically between high count MBL and low stage CLL and hence provides rational to recognize high count MBL and to regularly follow patients for progression.

show abstract

Update in large cell lymphoma: understanding the pathology report

Cited by 4 publications

References 132 publications

Differential diagnosis of sinonasal extranodal NK/T cell lymphoma and diffuse large B cell lymphoma on MRI

Differential diagnosis of sinonasal extranodal NK/T cell lymphoma and diffuse large B cell lymphoma on MRI

Ekspresi CD30 pada pasien Diffuse Large B-cell Lymphoma di RSUP Dr. Kariadi Semarang

2016 WHO Classification update—What's new in lymphoid neoplasms

Contact Info

Product

Resources

About